Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis
January 23, 2024 02:00 ET
|
Pluri Inc.
Pluri to leverage its proprietary 3D technology platform to develop cell-based products for the coffee industry under its new business vertical PluriAgtechThe rapidly growing $130 billion coffee...
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization
January 08, 2024 07:00 ET
|
Pluri Inc.
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction
December 21, 2023 07:00 ET
|
Pluri Inc.
Agreement signed following positive pre-clinical data demonstrating a one-time treatment with PLX-PAD significantly increased neurogenesis, offering immediate, long-term therapeutic effect in treating...
Pluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation
August 16, 2023 07:00 ET
|
Pluri Inc.
Results support the development of PLX-R18 for hematologic acute radiation syndrome (H-ARS), currently under a $4.2 million contract with the U.S. National Institutes of HealthPLX-R18 has the...
Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors
July 13, 2023 02:00 ET
|
Pluri Inc.
HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote...
U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome
July 11, 2023 02:00 ET
|
Pluri Inc.
Pluri's cell therapy is designed to be the first in class, effective treatment for ionizing radiation poisoning in the event of a large-scale nuclear incident.The work specified by the contract is...
Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products
April 27, 2023 07:00 ET
|
Pluri Inc.
Breakthrough system substantially increases cell production, with the potential to reach much higher productivity driven by platform’s significant scalability Flexible, industrial scale cell...
Israel’s Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity
March 13, 2023 08:00 ET
|
Pluri Inc.
HAIFA, Israel, March 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company,...
Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept
December 22, 2022 07:00 ET
|
Pluri Inc.
Milestones over the last year include launch of new Company strategy, joint venture with Tnuva Group in the field of cultivated meat and additional biologics technology partnership;Joint venture with...
Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
December 15, 2022 16:05 ET
|
Pluri Inc.
HAIFA, Israel, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, announced today that it has signed securities...